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BRAF V600E mutation in early-stage multiple myeloma: good
response to broad acting drugs and no relation to prognosis
EH Rustad1,2, HY Dai3, H Hov3,4, E Coward5,6, V Beisvag5, O Myklebost6,7, E Hovig6,7,8,9, S Nakken6,7, D Vodák6,7,10, LA Meza-Zepeda6,7,11,
AK Sandvik2, KF Wader12, K Misund1,2, A Sundan1,2, H Aarset3 and A Waage1,5,6,13
In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and
related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF V600E by allele-speciﬁc real-time
PCR (AS-PCR). Positive results were conﬁrmed by immunohistochemistry, Sanger sequencing and, in three patients from whom we
had stored puriﬁed myeloma cells, whole-exome sequencing. Eleven patients (5.3%) were BRAF V600E mutation positive by AS-PCR
and at least one other method. The fraction of mutated cells varied from 4 to 100%. BRAF V600E-positive patients had no
characteristic clinical phenotype except for signiﬁcantly higher levels of serum creatinine (125 versus 86 μmol/l) Seven of eleven
patients responded with at least very good partial response to alkylators, immunomodulatory agents or proteasome inhibitors.
Progression-free and overall survival were similar in patients with and without the mutation. By this integrated approach, we found
that patients with BRAF V600E mutation responded very well to broad acting drugs and there was no relation to prognosis in early-
stage myeloma. In particular, a large mutated cell fraction did not correlate with aggressive disease.
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INTRODUCTION
The oncogenic BRAF V600E mutation causes constitutive activa-
tion of the Ras-Raf-MEK-ERK (RAS) signaling pathway, stimulating
cellular growth, differentiation and survival.1 Although rare in
multiple myeloma, this mutation has attracted attention because
of its proven potential for targeted inhibition. In metastatic
malignant melanoma, which harbors BRAF V600E in 35–41% of
cases,2,3 treatment with the small-molecular BRAF V600E inhibitor
vemurafenib has resulted in improved overall survival (OS) in a
phase III clinical trial,4 although the long-term beneﬁt was limited
by the rapid acquisition of resistance. Promising results from BRAF
V600E inhibition have also been seen in patients with various
other cancers harboring BRAF V600E. These include anaplastic
thyroid carcinoma,5 pulmonary adenocarcinoma6 and hairy cell
leukemia.7
The clinical signiﬁcance of BRAF V600E in multiple myeloma has
been characterized in one study.8 Seven myeloma patients with
BRAF V600E had signiﬁcantly shorter OS (45 versus 105 months)
and increased incidence of extra medullary disease (EMD; 57%
versus 17%) compared with 251 patients with wild-type (wt) BRAF.
They also reported targeting BRAF V600E in one patient who
achieved a durable remission by vemurafenib. Since then, three
additional cases of refractory myeloma with BRAF V600E mutation
being treated with vemurafenib have been reported.9,10 Two
patients had short durations of response, whereas the third still
had ongoing response 4 months after initiation of therapy.
Lohr et al. recently published a genome sequencing study of
203 multiple myeloma patients, highlighting the vast genetic
heterogeneity of this disease.11 BRAF V600E appeared in both
major and minor clones, but rarely in the entire tumor cell
population.11,12 When a myeloma patient is exposed to various
treatment regimens, a changing and unpredictable pattern of
clonal resistance and dominance may occur.13,14 It has been
suggested that myeloma subclones harboring BRAF V600E might
have a survival advantage, and that once the BRAF V600E clone
becomes dominant, the disease becomes more aggressive.8,9
The genetic heterogeneity and changing clonal dominance of
multiple myeloma poses a challenge in deﬁning the conditions for
application of targeted therapy. Although exposing BRAF-mutated
myeloma cell lines to BRAF inhibition in vitro causes a reduction in
RAS-pathway activity, the opposite effect is seen in BRAF wt cells,
especially when a RAS mutation is also present.11 This paradoxical
effect indicates that BRAF inhibitor treatment may be harmful in
patients with small BRAF V600E-mutated subclones, underlining
the need of accurate characterization of candidates for BRAF
inhibitor treatment. Furthermore, it is also indicated that mutated
BRAF should not be targeted in patients with cells harboring
mutated RAS.15
Only 10 myeloma patients with BRAF V600E have been
described so far: 7 in a retrospective study and 3 case reports.
The biological and clinical signiﬁcance of this mutation is by no
means clariﬁed. In this retrospective study, we have analyzed
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biopsies from 209 patients with myeloma, 11 of whom harbor the
BRAF V600E mutation. In particular, we wanted to examine
patients carrying the BRAF V600E mutation and their relation to
clinical phenotype, treatment response and survival.
MATERIALS AND METHODS
Patient selection and data collection
The database at the Department of Pathology and Medical Genetics was
searched for biopsies classiﬁed as multiple myeloma or plasmacytoma
between 1996 and 2012, identifying biopsies from 209 patients with
multiple myeloma (n= 196) or smoldering myeloma (n=10) as deﬁned by
the International Myeloma Working Group (IMWG) criteria.16 In three cases,
it was not clear whether the patient had symptomatic disease. One
hundred and seventy-three patients (88.3%) were diagnosed with
symptomatic myeloma after 2000 when treatment with new drugs
(thalidomide) was introduced. A total of 188 patients had only bone
marrow biopsies, 14 only had a biopsy from extramedullary lesions, while 7
patients had both. Biopsies from 185 patients were obtained before a
relapse had occurred. From 22 patients, the biopsy was obtained later in
the course of disease. Time of biopsy was missing for two patients.
Patients who were alive at the time of inclusion were informed about
the study by a letter and given the option to withdraw. The Regional Ethics
Committee approved the study (REK 2165-2012).
OS was calculated from start of treatment until death. Progression-free
survival (PFS) was calculated from start of treatment until death or
progressive disease, whatever came ﬁrst. Presence of EMD was evaluated
based on patient records, imaging and biopsy descriptions. EMD was
classiﬁed in two groups: those extending from the bone marrow and those
growing independent of the bone marrow.17 Treatment response was
evaluated according to IMWG criteria.18 If serum M-protein was not
reduced by at least 50% following treatment (partial response, PR), the
patient was considered resistant to the drugs in question. Acquired
resistance developing after initial sensitivity for a speciﬁc drug was not
included in the evaluation.
BRAF mutation analysis
All biopsies were screened for BRAF V600E and BRAF K601N by PCR.
Biopsies with positive screening were examined by Sanger sequencing and
immunohistochemistry (IHC). Whole exome sequencing (WES) was
conducted in three patients from whom we had previously isolated and
stored CD138+ bone marrow cells in our myeloma biobank. Patients were
classiﬁed as BRAF V600E positive when the mutation was detected by
allele-speciﬁc real-time PCR (AS-PCR) and conﬁrmed by at least one other
detection method.
Isolation of genomic DNA and mutation analysis of BRAF
Genomic DNA from sections of bone marrow biopsies of myeloma patients
was isolated using QIAamp DNA FFPE Tissue Kit (Qiagen, Venlo,
Netherlands) according to the manufacturer’s instruction. DNA concentra-
tion was assessed by NanoDrop spectrophotometer (Thermo Fisher
Scientiﬁc, Waltham, MA, USA). AS-PCR for BRAF V600E and BRAF V600 wt
was performed using a Bio-Rad DNA Engine Opticon 2 Real-Time Cycler
(Bio-Rad Laboratories, Hercules, CA, USA). The reaction mix consisted of
1XGeneAmp PCR Gold buffer (Applied Biosystems, Thermo Fisher
Scientiﬁc), MgCl2 (1.5 mM), dNTP (0.4 mM), 6 μM of each primer, Taqman
probe (0.2 μM) and 1 U AmpliTaq Gold DNA polymerase, in a total volume
of 25 μl. The amount of 20 ng genomic DNA was applied for each PCR
reaction with the following program: denaturation at 94 °C for 10min
followed by 40 cycles of incubation at 94 °C for 30 s and then at 60 °C for
30 s. AS-PCR was performed for BRAF V600E mutation detection
with following sense primer for BRAF V600: 5′-TAGGTGATTTTGGTC
TAGCTACTGT-3′; BRAF V600E: 5′-TAGGTGATTTTGGTCTAGCTACTGA-3′ and
antisense primer: 5′-CCACAAAATGGATCCAGACA-3′ and Taqman probe: 5′-
TCGATGGAGTGGGTCCCATCA-3′. AS-PCR was performed for BRAF K601N
mutation detection with sense primer: 5′-AAACTCTTCATAATGCTTGCTCTG-3′
and antisense primer: 5′-GGACCCACTCCATCGACAT-3′ (K601) and 5′-
GGACCCACTCCATCGACAA-3′ (K601N).
The sensitivity of BRAF K601N detection was at least 1% and was tested
with BRAFK601N-positive cell line U266 in the background of BRAF V600
wt bone marrow biopsy. All BRAF V600E-positive samples shown by
AS-PCR were retested and reproduced. Sanger sequencing of BRAF exon
15 was used to verify BRAF V600E detected by AS-PCR. The sequence was
analyzed with a 3130 ABI capillary sequencer (Applied Biosystems).
Immunohistochemistry
IHC was carried out on formalin-ﬁxed parafﬁn-embedded samples, using
the mouse monoclonal anti-BRAFV600E antibody (clone VE1, Springer
Bioscience, Pleasanton, CA, USA). Slides were stained in a Dako Autostainer
Link 48 (Dako, Glostrup, Denmark) in a standard procedure using the
EnVisionTM FLEX+, Mouse, High pH (Link) kit from Dako. Brieﬂy, freshly cut
4-μm sections of formalin-ﬁxed parafﬁn-embedded tissue blocks were
pretreated with Target Retrieval Solution High (pH 9) for 20min at 85 °C
and incubated for 40min with a 1:100 dilution of the primary antibody.
The procedure included a secondary reagent and a HRP-labeled polymer.
3,3′-Diaminobenzidine was used for chromogenic detection. Slides were
subsequently washed in water, incubated with 0.5 % (w/v) copper sulphate
for 3 min and counterstained with hematoxylin for 15 s. The antibody was
tested out on formalin-ﬁxed parafﬁn-embedded samples from AS-PCR
BRAF V600E-positive and -negative malignant melanoma, adenocarcinoma
of the colon, and hairy cell leukemia. Sections from the myeloma patients
with positive AS-PCR were evaluated independently by two hematopathol-
ogists. As the work progressed, we realized that the percentage of
BRAFV600E-positive plasma cells varied substantially between patients. We
therefore estimated the proportion of positive plasma cells in quartiles
compared with slides stained with antibodies against CD138, or kappa or
lambda light chains. Sections from 20 myeloma patients with BRAF V600E-
negative AS-PCR were investigated for BRAF V600E by IHC. They were all
found negative.
Patient myeloma cells and mononuclear cells
CD138-positive myeloma cells were isolated from bone marrow samples
obtained from the Norwegian Myeloma Biobank, using a RoboSep
automated cell separator and a Human CD138 Positive Selection Kit
(StemCell Technologies, Grenoble, France).19 The purity of plasma cells
after isolation was above 90%. Mononuclear cells were isolated from whole
blood using a Vacutainer cell preparation tube with sodium citrate (BD,
Franklin Lakes, NJ, USA) according to the manufacturer’s instructions.
Whole-exome sequencing
DNA was extracted from mononuclear blood cells and puriﬁed CD138 cells
from bone marrow using QIAamp DNA Mini Kit (Qiagen, Germantown, MD,
USA) according to the manufacturer’s instructions. Exome sequencing
libraries were prepared from 1 μg genomic DNA using the SureSelectXT
target enrichment system for Illumina paired-end sequencing libraries
(Agilent Technologies, Santa Clara, CA, USA), according to the manufac-
turer’s instructions. Brieﬂy, the DNA was fragmented using the Covaris
M220 system (Covaris, Woburn, MA, USA). The DNA fragments (183± 3 bp)
were end-repaired using T4 DNA polymerase, Klenow DNA polymerase and
T4 polynucleotide kinase (PNK), followed by puriﬁcation using AMPure XP
beads (Beckman Coulter, Brea, CA, USA). Fragments were A-tailed using
Klenow DNA polymerase and dATP and puriﬁed using AMPure XP beads.
Indexing adapters for sequencing were ligated to the DNA fragments,
followed by puriﬁcation using AMPure XP beads. The adapter-ligated
libraries were ampliﬁed for six PCR cycles, followed by a second
puriﬁcation using AMPure XP beads. The quality of the enriched libraries
was evaluated using the 2100 Bioanalyzer and a DNA 1000 kit (Agilent
Technologies, Santa Clara, CA, USA) and quantitative PCR. Exon capture
was performed from 1 μg of each sequencing library using the
SureSelectXT Human All Exon V5 target 50 Mb kit (Agilent Technologies).
Brieﬂy, the fragments in the library were hybridized to capture probes (20 h
at 65 °C), unhybridized material was washed away and the captured
fragments were ampliﬁed for 10 PCR cycles, followed by puriﬁcation using
AMPure XP beads. The quality of the enriched libraries was evaluated using
the 2100 Bioanalyzer and a High-Sensitivity DNA-kit (Agilent Technologies).
The adapter-ligated fragments were quantiﬁed by quantitative PCR using
the KAPA SYBR FAST library quantiﬁcation kit for Illumina Genome Analyzer
(KAPA Biosystems, Woburn, MA, USA). A 20 pM solution of the sequencing
libraries was subjected to cluster generation on the cBot instrument
(Illumina, Inc., San Diego, CA, USA). Paired-end sequencing was performed
for 2 × 100 cycles on a HiSeq2500 instrument (Illumina, Inc.), according to
the manufacturer’s instructions.
Base calling was done on the HiSeq instrument by RTA 1.17.21.3. Fastq
sequence ﬁles were generated using CASAVA 1.8.2 (Illumina, Inc.).
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Sequence analysis and somatic variant calling
Paired-end sequencing reads of length 100 bp were aligned to the human
reference genome (hg19, without haplotype chromosomes and unplaced
contigs) using the Novoalign tool (version 2.08.03, http://www.novocraft.
com). Novoalign was run with custom options set for expected pair-end
insert size correction (‘-i PE 220,60’) and multiple mapper reporting (‘-r All
10’). Sequencing reads that did not map properly to the genome (that is,
no match, multiple matches, paired reads matching different chromo-
somes, or paired reads matching the same orientation) were excluded
from the analysis. PCR-derived duplicate reads (judged by mapping
location and nucleotide sequence) with lowest sum of base qualities were
also discarded. Re-alignment was performed around indels with GATK
RealignerTargetCreator and IndelRealigner tools (version 2.3.9-ge5ebf34),
followed by an application of Picard FixMateInformation (http://picard.
sourceforge.net, version 1.84).20 Base quality recalibration was done with
GATK BaseRecalibrator. Among the tumor samples, we obtained a
minimum sequencing coverage of 100× for 85.7% of the exonic-
targeted regions. Similarly, for the matching control samples, a minimum
sequencing coverage of 50 × was obtained for 87% of the exonic-targeted
regions.
MuTect (version 1.1.4) was applied on the matched tumor-control
alignments to identify somatically acquired point mutations.21 MuTect
employs a Bayesian classiﬁer to detect somatic mutations with very low
allele fractions, requiring only a few supporting reads, followed by carefully
tuned ﬁlters that ensure high speciﬁcity. To minimize the number of
potentially false positive variants, all variants that passed MuTect ﬁlters
were in addition subject to the following hard ﬁlters: a minimum
sequencing coverage of 14× at the variant site in the tumor and a
minimum of 5 positive quality reads supporting the alternative allele, a
minimum sequencing coverage of 8 × in the control and less than 5% of
the reads supporting the alternative allele. An exception from this was
made for the BRAF V600E mutation, which was already detected by AS-PCR
in all three patients. In this context, the mutation can be considered
present with only 2–3 supporting reads in the tumor sample.
To understand the functional role of identiﬁed variants, all variants were
subject to a computational annotation workﬂow that included ANNOVAR
(released on 23 August 2013, using RefSeq as the gene model), COSMIC
(known somatic cancer variants and Cancer Gene Census, v68), PFAM
(protein domain information, v27.0), UniProt (functional protein properties,
release 2014_05), PROSITE (predicted functional protein sites, Release
20.100 of 19Feburary 2014), the Drug Gene Interaction Database
(druggable targets, version 1.63) and dbNSFP (computational predictions
of effect of coding variants, v2.4).22–28
Image processing
Histology images were captured at room temperature with a Nikon eclipse
Ci microscope (Nikon Gmbh, Düsseldorf, Germany) with a Lumenera
Inﬁnity 2 camera and Inﬁnity analyze software, release 6.2 (Lumenera
Corporation, Ottawa, Ontario, Canada).
Images and graphic materials were processed in Adobe Illustrator v 6
and Adobe Photoshop CS6.
Statistical analysis
OS and PFS in BRAF V600E and BRAF wt groups were compared by
Kaplan–Meier estimates and Log Rank test. Differences in clinical
parameters were evaluated by T-test, Mann–Whitney U-test or Fisher’s
exact test. Level of statistical signiﬁcance was set at Po0.05, and P-values
were two-tailed. Statistical analysis was carried out by SPSS v. 21
(IBM Corporation, Armonk, NY, USA).
RESULTS
Prevalence of BRAF V600E mutation
BRAF V600E was detected by AS-PCR in bone marrow or EMD from
11 out of 209 patients (5.3%) with multiple myeloma (Table 1).
Two additional patients with positive BRAF V600E AS-PCR were
classiﬁed as negative because the mutation was not conﬁrmed by
another method. The prevalence of BRAF V600E mutation in EMD
was 4.8% (1/21). No BRAF K601N mutations were detected by AS-
PCR screening of 190 bone marrow biopsies.
Evaluation of BRAF V600E-positive clones
The fraction of BRAF V600E-positive cells as estimated by IHC is
shown in Table 1. The growth patterns of BRAF V600E-positive
cells were different in different areas of the biopsies and differed
between patients. The distribution of positive cells was either in
conﬂuent sheets or as disseminated cells. In areas where the bone
marrow was packed with CD138-positive myeloma cells
(Figure 1a), the proportion of BRAF V600E-positive cells varied
substantially (Figure 1b) indicating different myeloma subclones.
The presence of single scattered positive cells among a
predominating negative myeloma clone rules out the possibility
of false negative areas because of technical error, ﬁxation
Table 1. Analysis of 11 patients with BRAF V600E
Patient
no.
BRAF
V600E fraction
IHC (%)
BRAF
V600E fraction
WES (%)
BRAF
V600E
Sanger
NRAS/KRAS
fraction WES
Overall survival
(months)
Best response
to treatment
Sensitive,
⩾ PR
Resistant,
oPR
1 75–100 86 Pos 0 48 VGPR MP
1a ND 28 ND 0 48 VGPR MP
2 75–100 ND Neg ND 77b PR CP MP, T, BP, LP
3 75–100 ND Pos ND 89 CR MPT, TD, T
4 50–75 ND Pos ND 11b Missing data Missing data Missing data
5 50–75 ND Pos ND 51b nCR MPT, BD, MPB, LD
6 25–50 ND Neg ND 79b VGPR CD+HDSCT,
BD+HDSCT
CBD, L, T
7 25–50 ND Neg ND 23b PR MP, LD MPT
8 o25 0 Neg KRAS p.Q61H, 10
%
17 VGPR CBD+HDSCT
9 o25 ND Pos ND 0b Missing data Missing data Missing data
10 o25 ND Pos ND 238* nCR VAD, VAD+HDSCT,
CD, BD, CBD
M2 (M, C, P, V,
karmustine)
11 neg 4 Neg NRAS p.Q61K, 94
%
16 VGPR MPT, T None
Abbreviations: A, adriamycine; B, bortezomib; C, cyclophosphamide; D, dexamethasone; HDSCT, high-dose therapy and autologous stem cell transplant;
L, lenalidomide; M, melphalan; nCR, near CR (CR not conﬁrmed by bone marrow aspiration); ND, not determined; Neg, negative; Pos, positive; P, prednisone;
T, thalidomide; V, vincristine. All biopsies were from bone marrow with the exception of that from patient 3, which was from an osteolytic lesion in the skull.
Biopsies were from relapsed disease for patients 6 and 10, and at time of diagnosis for the remaining patients. Results from IHC are reported as the estimated
percentage of CD138 or kappa/lambda-positive cells that are also positive for BRAF V600E. aBone marrow aspirate obtained after treatment for ﬁrst relapse.
bOverall survival is calculated from diagnosis to death (*) or censoring date.
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differences and so on. It also indicates that these BRAF V600E-
positive cells do not possess a growth advantage over the
surrounding negative cells in these areas.
Clone size was also evaluated by WES in patients 1, 8 and 11,
from whom we had available material (Table 2). Exomes from the
myeloma cells and blood mononuclear cells were sequenced at a
depth of 100-fold and 50-fold, respectively (for at least 80 % of
exons). Clone fraction of BRAF V600E was comparable with that
found by IHC in patient 1 who had a dominating clone, whereas
the correspondence was not perfect for small clones in patients 8
and 11.
Additional information from WES
Among the top 11 recurrently mutated genes listed in Lorh et al.,11
we found mutations only in BRAF, NRAS and KRAS. Combined
mutations in BRAF/NRAS or BRAF/KRAS were found in two of three
investigated patients. Both had small fractions of BRAF mutated
cells (Tables 1 and 2).
No genes with coding mutations after ﬁltering were shared
between all three patients. Patients 1 and 11 shared one gene
(ATXN1), patients 8 and 11 shared one gene (HCFC2) and patients
1 and 8 shared three genes (IQSEQ3, PCMTD1, PNRC2). For
complete list of mutations, see the online Supplementary
Information (Supplementary Table 1).
Clinical characteristics, drug sensitivity and survival of patients
with BRAF V600E mutation
Creatinine was signiﬁcantly higher in the BRAF V600E mutated
group (Table 3). Other characteristics were distributed equally or
non-signiﬁcantly different between the two groups. This was also
the case for characteristics that might inﬂuence outcome, like age,
ISS (International Staging System) stage and exposition to newer
drugs or high-dose therapy and autologous stem cell transplant
(Table 3).
There was no signiﬁcant difference in PFS (data not shown) or
OS (Figure 2) between the BRAF V600E-positive and -negative
groups. The result was the same also for ﬁve patients harboring
BRAF V600E in more than 50% of the plasma cells. There was no
difference in the prevalence of EMD (Table 3).
BRAF V600E-positive patients were sensitive to a variety of
treatment regimens (Table 1). Excluding one patient with missing
response data, 7 of 10 patients responded with very good partial
response (VGPR) or better. All three patients receiving high-dose
therapy and autologous stem cell transplant responded. There
were sensitivity and resistance to alkylators, immunomodulatory
agents and proteasome inhibitors without any particular pattern.
Two patients with NRAS or KRAS mutation combined with a small
BRAF V600E clone responded with VGPR.
DISCUSSION
In this study, we have analyzed clone size and growth pattern of
BRAF V600E-positive cells related to clinical information, treatment
response and survival. Patients harboring BRAF V600E clones of
any size responded very well to treatment as 7 of 11 patients
achieved VGPR or better to at least one treatment regimen. We
conclude that these patients can be highly sensitive to broad
acting drugs like alkylators, immunomodulatory agents and
proteasome inhibitors.
When there is a 490% reduction of the total clonal cell mass,
we can infer that also the V600E-positive cells are sensitive to
broad acting drugs in most cases.
We detected the BRAF V600E mutation in 5.3% of patients with
multiple myeloma. In 1.4% (3 patients), there was a dominating
clone with more than 75% BRAF V600E mutated cells, which can
Figure 1. IHC showing fraction and growth pattern of BRAF V600E mutated plasma cells. Microscopic images of bone marrow biopsy from
patient 4 (Table 1). (a) The bone marrow was in large areas packed with CD138-positive myeloma cells. × 100 magniﬁcation. (b) The same area
as in a with the BRAF V600E antibody. On the left side, almost none of the myeloma cells were positive, whereas the mutant clone
predominated on the right side. × 100 magniﬁcation. (c and d) High-power ﬁeld (×400) images from the area to the left (c) and right (d) side in
image a and b. (c) Single scattered BRAF V600E-positive myeloma cells among predominating negative myeloma cells. In d, almost all
myeloma cells were BRAF V600E positive.
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be regarded as a valid rationale for BRAF inhibitor treatment.
Translation of the mutated gene to protein, which is another
prerequisite for inhibitor treatment, was demonstrated by IHC in
10 of 11 patients. Examples of excellent effect of speciﬁc BRAF
V600E inhibition have been published.9,10 However, these patients
have been in a late stage with acquired resistance to several
drugs. Our analysis is based on early-stage disease, which may be
very different. Taken together, the clonal heterogeneity that is
frequently present and the broad sensitivity of BRAF V600E-
positive clones indicate that broad acting drugs still should be a
backbone of the treatment regime. If speciﬁc BRAF inhibition is
applied, there is a rationale to give it in addition to broad acting
drugs. The beneﬁt of speciﬁc BRAF inhibition in this situation of
course needs to be tested separately in a prospective clinical trial.
PFS and OS were equal in patients with and without BRAF
mutation V600E. Creatinine was the only factor that was
signiﬁcantly different. There were smaller non-signiﬁcant differ-
ences in ISS stage III and exposition to thalidomide, bortezomib,
lenalidomide and carﬁlzomib, which were more frequent in the
V600E group, and for ISS stage II and high-dose therapy and
autologous stem cell transplant, which was more frequent in the
non-V600E group. The three patients with 475% BRAF V600E
mutated clone all had relatively indolent disease courses with OS
of 48, 77 and 89 months. We conclude that the presence of BRAF
V600E at diagnosis or early in the disease, regardless of clone size,
is not correlated with particularly aggressive disease in our cohort
of patients. Renal damage was associated with BRAF V600E
mutation, but this needs to be conﬁrmed by other studies to
establish a true relation. Except for this, we found no characteristic
clinical phenotype related to the BRAF V600E mutation. We found
no BRAF K601N mutations in the 190 patients screened, which is
in line with the previously reported prevalence of 0 and 1.9%.11,29
WES conﬁrmed the presence of the actual BRAF V600E mutation
in two of three patients that were analyzed. We should keep in
mind that the sequencing was adapted to whole-exome scanning
(depth of coverage of approximately 100 × ) and this resulted in a
sensitivity inferior to that obtained by AS-PCR and IHC. Lohr et al.
calculated that they could detect clone sizes down to 10% with a
mean coverage of 89 × .11 In our study, the three patients were all
found to be positive for the BRAF V600E mutation by PCR, and two
of them additionally by IHC. This allows for a higher signiﬁcance
level for a statistical evaluation of positive result by sequencing,
that is, we are able to detect smaller clones. The lower sensitivity
of WES can easily be compensated at a low cost if targeted
sequencing of a limited number of genes is carried out.
The clone size as estimated by IHC and WES corresponded well
in the patient with a dominating BRAF V600E mutated clone, but
less so in patients with a smaller percentage of cells carrying the
mutation. Random differences in the sampling and bone marrow
composition may explain this difference. Both methods add
unique information. IHC visualized differences in the growth
pattern of BRAF V600E mutated cells, which appeared in a tumor-
like manner or as disseminated cells. Whether this has an
association to signaling activity or tumor growth remains to
be seen.
Of the top 11 list of recurrent mutations published by Lohr et al.,11
we only detected mutations in BRAF, KRAS and NRAS. RAS
mutations are of particular interest because in vitro studies
indicate that their presence may imply a paradoxical effect of
BRAF inhibitors. This effect is not yet demonstrated in patients, but
should be taken into consideration if BRAF mutation inhibitor
treatment is considered.
Table 2. Clinical characteristics of patients with or without BRAF
V600E mutation
BRAF V600E
positive, n= 11
BRAF V600E
negative, n= 198
P-value
Age at diagnosisa, years 69 (27) 68 (18) 0.896
Sex (male) 6/11 (54.5%) 126/198 (64.6%) 0.538
Light chain disease 3/11 (27.3%) 32/187 (17.1%) 0.888
Non-secretory 0/11 3/187 (1.6%)
IgG 5/11 (45.5%) 96/187 (51.3%)
IgA 3/11 (27.3%) 46/187 (24.6%)
IgD 0/11 6/187 (3.2%)
IgE 0/11 1/187 (0.5%)
IgM 0/11 3/187 (1.6%)
Non-secretory 0/11 3/174 (1.7%) 0.375
Kappa 5/11 (45.5%) 112/174 (64.4%)
Lambda 6/11 (54.5%) 59/174 (33.9%)
ISS stage 1 2/7 (28.6%) 40/141 (28.4%) 0.891
ISS stage 2 2/7 (28.6%) 54/141 (38.3%)
ISS stage 3 3/7 (42.9.%) 47/141 (33.3%)
S-creatinine, μmol/la 125 (463) 86 (48) 0.023
Corrected calcium, mmol/la 2.52 (0.26) 2.48 (0.37) 0.878
Hemoglobin, g/dlb 11.9 (2.4) 11.0 (2.1) 0.257
Albumin, g/la 38.0 (10) 35.0 (8) 0.512
Beta-2-microglobulin, mg/la 5.0 (5.4) 4.2 (4.0) 0.907
Bone disease present 9/10 (90%) 105/131 (80.2%) 0.687
EMD 4/11 (36.4%) 72/167 (43.1%) 1
EMD separate from bone 1/11 (9.1%) 25/167 (15.0%) 1
Treated with novel drugsc 9/10 (90%) 133/178 (74.7%) 0.455
Treated with HDSCT 3/11 (27%) 72/184 (39%) 0.749
Abbreviations: EMD, extra medullary disease; HDSCT, high-dose therapy
and autologous stem cell transplant. aParameters who do not follow a
normal distribution are presented as median with interquartile range.
bParameters with a normal distribution are presented with mean and
standard deviation. cNovel drugs include thalidomide, bortezomib,
lenalidomide, carﬁlzomib.
Table 3. Summary of WES from three patients positive for BRAF V600E by PCR
Patient 1 Patient 8 Patient 11
Total single nucleotide variants in exons 145 75 74
Synonymous mutations 33 12 14
Missense mutations 75 36 41
Nonsense mutations 4 4 1
Mutation in untranslated region 24 16 13
Mutations in splice sites 9 7 5
Detection of BRAF V600E mutation Mutation present in
68/157 reads (43%)
Mutation present in
0/100 reads
Mutation present in 2/99
reads (2%)
Estimated BRAF V600E clone size 86% 0% 4%
Detection of RAS-mutations None detected KRAS Q61H mutation present
in 7/146 reads (5%)
NRAS Q61K mutation present
in 97/205 reads (47%)
Estimated RAS-mutated clone size 0% 10% 94%
The percentages of mutated tumor cells are estimated given that each cell contains one copy of the mutated gene and that purity of isolated tumor cells is
near 100%.
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Patient 8 had NRAS mutation Q61K in approximately 94% of
tumor cells and BRAF V600E in 4%. Patient 11 had KRAS Q61H
mutation in 10% of tumor cells, and a small clone positive for
BRAF V600E by IHC that was not detected by WES. These two
cases conﬁrm that several mutations in the same signaling
pathway can be present in one patient, but not necessarily in the
same tumor cells.11 Both these patients responded with VGPR.
Several of our observations contrast those of Andrulis et al.,8
who found a BRAF V600E mutation four times more frequent in
EMD compared with bone marrow. They also found signiﬁcantly
shorter OS in patients with BRAF V600E, and reported that the
disease seemed to become more aggressive as soon as the BRAF
V600E mutation was present. This view is supported by three
recently published case reports of very aggressive BRAF V600E
mutated myeloma, which quickly became refractory to
conventional treatment.9,10 We could not conﬁrm these
observations. The differences between the studies may be
explained by different selection of patients and random variation.
Evidently, patients with BRAF V600E can have aggressive,
treatment refractory disease, but also indolent disease as
documented in our study.
By this integrated approach to early-stage multiple myeloma,
we found that patients with BRAF V600E mutation responded very
well to broad acting drugs and there was no relation to prognosis
in early stage myeloma. In particular, a large mutated cell fraction
did not herald aggressive disease. This study demonstrates that
the role of BRAF mutation V600E is more diverse than previously
assumed.
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